Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00250_DB06708_nanopub.RA_a_Z5cX2JR0UQk5ODig2s2G5jy0cUu7yQ8HOqdEMLsE#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00250_DB06708 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00250_DB06708 label "DDI between Dapsone and Lumefantrine - Concomitant therapy may increase the risk of adverse hemolytic reactions. Monitor patients closely for symptoms of hemolytic reactions during concomitant therapy. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, methoglobulin reductase deficiency or hemoglobin M are at higher risk of experiencing hemolytic reactions. [drugbank_resource:DB00250_DB06708]" assertion.
- drugbank_resource:DB00250_DB06708 identifier "drugbank_resource:DB00250_DB06708" assertion.
- drugbank_resource:DB00250_DB06708 title "DDI between Dapsone and Lumefantrine - Concomitant therapy may increase the risk of adverse hemolytic reactions. Monitor patients closely for symptoms of hemolytic reactions during concomitant therapy. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, methoglobulin reductase deficiency or hemoglobin M are at higher risk of experiencing hemolytic reactions." assertion.
- drugbank:DB00250 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00250_DB06708 assertion.
- drugbank:DB06708 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00250_DB06708 assertion.